News

AAA Opens Lutathera Expanded Access Program In U.S. to Eligible Patients And Announces Forthcoming NDA Filing to FDA and EMA.

AAA today announced that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program, Lutathera is being made available for patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy. Healthcare professionals and patients can learn more about the Lutathera EAP by visiting www.clinicaltrials.gov (trial number: NCT02705313). To read more visit AAA's website.

2016 Neuroendocrine Tumor Patient ConferenceUCSF Diller navy
Hosted by:UCSF Helen Diller Family Comprehensive Cancer Center
In cooperation with NorCal CarciNET Community, NET Research Foundation, Stanford University Medical Center

Sunday, January 24, 2016 - 9:00 am to 4:30 pm

View the recording of the LiveStream  

Read more: 2016 Bay Area Neuroendocrine Patient Conference - Hosted by UCSF

In addition to the NETTER1 trial presented at the European Cancer Congress, two other phase 3 NET clinical trials presented their results.

Everolimus conferred a statistically significant and clinically meaningful PFS benefit with an acceptable safety profile in patients with advanced, progressive neuroendocrine tumors of the lung or gastrointestinal region, according to phase 3 trial results (Radiant4). 

Read more: Updates from ESMO

On October 20, 2015 the Society for Nuclear Medicine and Molecular Imaging and the NorCal CarciNET Community hosted a webinar on PRRT featuring Dr. Ed Wolin and Dr. Eric Mittra. NorCal CarciNET's Josh Mailman facilitated the ensuing question and answer session. Over 95 participated in the webinar which can be viewed below. In addition the slides that were used are available by clicking here. Guidelines for the use of PRRT are avialble from the PRRTInfo.org website. 

You may use the share icon (looks like an airplane) to embed this video in another site.

The results from the first large scale randomized control trial of PRRT were released today in Vienna, Austria showing increased progression free survival compared to high dose octreotide LAR.

PRRT while available in many parts of the world has not yet been approved for use pending prospective randomized clinical trails (RCT). Having a positive RCT for PRRT will greatly expand access and availability to PRRT around the world. Click here to download the full release.

  1. Two NET Abstracts Set for Presentation at Presidential Session of ECC 2015
  2. Lexicon Reports Positive Top-Line Results for Phase 3 Telotristat Etiprate Study
  3. NorCal CarciNET President awarded
  4. Patient Program at 3rd Theranostic World Congress
  5. Special Meeting Annoucement
  6. JNCI Monograph on Integrative Oncology